Literature DB >> 9337149

The activated anaplastic lymphoma kinase increases cellular proliferation and oncogene up-regulation in rat 1a fibroblasts.

A Wellmann1, V Doseeva, W Butscher, M Raffeld, P Fukushima, M Stetler-Stevenson, K Gardner.   

Abstract

More than 60% of anaplastic large-cell lymphomas (Ki-1 lymphoma) are associated with a t(2;5)(p23;q35) translocation that produces an 80 kDa hyperphosphorylated chimeric protein (p80) derived from the fusion of the anaplastic lymphoma kinase (ALK) with nucleophosmin (NPM). The NPM-ALK chimeric gene is an activated tyrosine kinase that has been shown to be a potent oncogene. We have developed a cellular model for the study of p80 action in rat 1a fibroblasts. Expression of cDNA's encoding NPM-ALK (p80) in rat 1a fibroblasts induces anchorage-independent growth in soft agar and promotes foci formation in culture. Cells expressing exogenous p80 showed significantly increased proliferation characterized by accelerated cell cycle entry into S-phase. Consistent with increased G0/G1 to S-phase transition, there is also marked up-regulation of cyclin A and cyclin D1 expression. In addition, p80 transformed cells showed elevated expression of several immediate early genes involved in cellular proliferation, including fos, jun, and c-myc. DNA binding analysis of nuclear extracts prepared from p80 transformed cells reveal marked up-regulation of AP-1 DNA binding activity. Functional AP-1-specific transfection assays also show up-regulation of AP-1-dependent transcriptional activation. These finding demonstrate that p80 transformed rat 1a fibroblast can be a highly useful model system for the molecular and biochemical characterization of the mechanisms of action of this interesting new oncogene.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9337149     DOI: 10.1096/fasebj.11.12.9337149

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  20 in total

1.  Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes.

Authors:  Roberto Piva; Elisa Pellegrino; Michela Mattioli; Luca Agnelli; Luigia Lombardi; Francesco Boccalatte; Giulia Costa; Bruce A Ruggeri; Mangeng Cheng; Roberto Chiarle; Giorgio Palestro; Antonino Neri; Giorgio Inghirami
Journal:  J Clin Invest       Date:  2006-11-16       Impact factor: 14.808

Review 2.  Pathobiology of ALK+ anaplastic large-cell lymphoma.

Authors:  Hesham M Amin; Raymond Lai
Journal:  Blood       Date:  2007-05-22       Impact factor: 22.113

3.  Fusion tyrosine kinase NPM-ALK Deregulates MSH2 and suppresses DNA mismatch repair function novel insights into a potent oncoprotein.

Authors:  Leah C Young; Kathleen M Bone; Peng Wang; Fang Wu; Benjamin A Adam; Samar Hegazy; Pascal Gelebart; Jelena Holovati; Liang Li; Susan E Andrew; Raymond Lai
Journal:  Am J Pathol       Date:  2011-05-24       Impact factor: 4.307

4.  Differential expression of aurora-A kinase in T-cell lymphomas.

Authors:  Rashmi Kanagal-Shamanna; Norman L Lehman; James P O'Donnell; Megan S Lim; Daniel S Schultz; Dhananjay A Chitale; Carlos E Bueso-Ramos; L Jeffrey Medeiros; Kedar V Inamdar
Journal:  Mod Pathol       Date:  2013-02-15       Impact factor: 7.842

5.  Autocrine release of interleukin-9 promotes Jak3-dependent survival of ALK+ anaplastic large-cell lymphoma cells.

Authors:  Lin Qiu; Raymond Lai; Quan Lin; Esther Lau; David M Thomazy; Daniel Calame; Richard J Ford; Larry W Kwak; Robert A Kirken; Hesham M Amin
Journal:  Blood       Date:  2006-06-08       Impact factor: 22.113

6.  ALK expression in extranodal anaplastic large cell lymphoma favours systemic disease with (primary) nodal involvement and a good prognosis and occurs before dissemination.

Authors:  R L ten Berge; J J Oudejans; G J Ossenkoppele; K Pulford; R Willemze; B Falini; A Chott; C J Meijer
Journal:  J Clin Pathol       Date:  2000-06       Impact factor: 3.411

Review 7.  Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-Dependent Kinase 4/6 Inhibitor in Various Solid Tumors.

Authors:  Debu Tripathy; Aditya Bardia; William R Sellers
Journal:  Clin Cancer Res       Date:  2017-03-28       Impact factor: 12.531

8.  Involvement of Grb2 adaptor protein in nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-mediated signaling and anaplastic large cell lymphoma growth.

Authors:  Ludovica Riera; Elena Lasorsa; Chiara Ambrogio; Nadia Surrenti; Claudia Voena; Roberto Chiarle
Journal:  J Biol Chem       Date:  2010-06-16       Impact factor: 5.157

9.  p130Cas mediates the transforming properties of the anaplastic lymphoma kinase.

Authors:  Chiara Ambrogio; Claudia Voena; Andrea D Manazza; Roberto Piva; Ludovica Riera; Laura Barberis; Carlotta Costa; Guido Tarone; Paola Defilippi; Emilio Hirsch; Elisabetta Boeri Erba; Shabaz Mohammed; Ole N Jensen; Giorgio Palestro; Giorgio Inghirami; Roberto Chiarle
Journal:  Blood       Date:  2005-08-16       Impact factor: 22.113

10.  NPM-ALK up-regulates iNOS expression through a STAT3/microRNA-26a-dependent mechanism.

Authors:  Haifeng Zhu; Deeksha Vishwamitra; Choladda V Curry; Roxsan Manshouri; Lixia Diao; Aarish Khan; Hesham M Amin
Journal:  J Pathol       Date:  2013-03-14       Impact factor: 7.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.